Evidence map›Paper›PMID 42023251›Full record

ReviewIbrain2026

Molecular imprinting for neurology: Materials, applications, and limitations.

Xiaohan Ma, Yingqi Ma, Claudia Marino, Alessandro Poma

Abstract readReview
In one paragraph

Review in Ibrain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaohan MaDivision of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute Royal Free Hospital, UCL Medical School London UK.
Yingqi MaDivision of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute Royal Free Hospital, UCL Medical School London UK.
Claudia MarinoDepartment of Neurology, Sealy Institute for Drug Discovery and Mitchell Center for Neurodegenerative Diseases The University of Texas Medical Branch Galveston Texas USA.
Alessandro PomaDivision of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute Royal Free Hospital, UCL Medical School London UK.ORCID https://orcid.org/0000-0003-2913-0389

Funding

Wellcome Trust
6 · The paper itself

Abstract

Neurological disorders represent one of the most pressing challenges in contemporary medicine, requiring tools that enable early diagnosis, targeted treatment, and deeper mechanistic understanding. Conventional biological agents such as antibodies, though widely used, often face limitations related to stability, brain penetration, cost, and integration into real-world platforms. Molecularly imprinted polymers (MIPs) have emerged as a promising synthetic alternative, capable of mimicking the molecular recognition functions of biological systems while offering enhanced robustness and customisability. MIPs provide key advantages, including high thermal and chemical stability, reusability, and design flexibility, making them especially attractive for neurological applications. In this review, we begin by presenting an overview of the main MIP formats applied in neurology, detailing their preparation, characterisation, and application-relevant advantages and limitations. We then explore the most actively investigated areas of MIP use in neurological diagnostics, research, and therapy, with a particular focus on: (i) nerve agents, (ii) neurotransmitters, and biomarkers, and (iii) drug development, drug delivery, and direct biological activity. Finally, we discuss the key challenges that currently hinder the clinical translation of MIPs in neurology, including poor biodegradability, in vivo biocompatibility concerns, and scalability, along with emerging strategies aimed at overcoming these barriers. We hope this analysis will serve as a useful reference for neuroscientists seeking novel material-based tools, as well as for materials scientists aiming to develop neurological applications of molecular imprinting.

Indexed as

brainmolecular imprintingmolecularly imprinted polymers (MIPs)neurologytherapeutics

Identifiers

PMID42023251
PMCPMC13097389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.